Australian Clinical Labs Limited (ASX:ACL)

Market Cap	524.73M
Revenue (ttm)	728.27M
Net Income (ttm)	30.67M
Shares Out	194.35M
EPS (ttm)	0.15
PE Ratio	17.58
Forward PE	14.37
Dividend	0.13 (4.63%)
Ex-Dividend Date	Mar 27, 2025

Volume	421,575
Average Volume	935,389
Open	2.730
Previous Close	2.710
Day's Range	2.690 - 2.730
52-Week Range	2.520 - 3.860
Beta	1.07
RSI	39.29
Earnings Date	Aug 26, 2025

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offe...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,900
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In 2024, Australian Clinical Labs's revenue was 696.37 million, a decrease of -0.10% compared to the previous year's 697.07 million. Earnings were 23.93 million, a decrease of -33.33%.